Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2024-06-14

Clinical Trial Update: A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan

View source ↗

Summary

A completed survey in Japan evaluating how pharmacists utilize Risk Management Plan materials for ixazomib (NINLARO) with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NINLARO (ixazomib)

Snippet

Sponsor: Takeda | Conditions: Multiple Myeloma | Status: COMPLETED | Results posted: 2024-06-14